Abstract P178 Table 2

Clinical manifestations and complications

Lupus nephritisWithout Lupus nephritisP value
Number of patients, n (%) 45 (36%) 89 (66.4%)
SLICC at last clinical assessment 0 0 (0- 0.5) 0.872
SLEDAI at last clinical assessment 2 (0- 4) 0 (0- 2) 0.123
BILAG at last clinical assessment 1 (0- 1.75) 1 (0- 1) 0.822
Constitutional symptoms 26 (80%) 67 (75.3%) 0.666
Mouth ulcers 31 (68.8%) 61 (68.5%) 0.258
Skin involvement 40 (88.9%) 73 (82%) 0.150
Arthritis 37 (82.2%) 71 (79.8%) 0.309
Myositis 5 (11.1%) 16 (18%) 0.451
Neuropsychiatric involvement 15 (33.3%) 19 (21.3%) 0.146
Cardiorespiratory involvement 12 (26.7%) 20 (22.5%) 0.669
Gastrointestinal involvement 8 (17.8%) 18 (20.2%) 0.724
Ophthalmic involvement 4 (8.9%) 9 (10.1%) 0.108
Haematological involvement 26 (57.8%) 44 (49.4%) 0.464
Hypertension 8 (17.8%) 6 (6.7%) 0.071
Stroke 1 (2.2%) 2 (2.2%) 1.000
Low bone mineral density 16 (35.5%) 11 (12.4%) 0.008*
Malignancy 1 (2.2%) 1 (1.1%) 1.000
  • Numbers are medians (interquartile ranges) unless otherwise stated. *p<0.05 is significant